Mona Mohammed Abdelrahman
Sohag, Egypt
NCT Number: NCT04779905
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with metabolic syndrome, obesity, and type II diabetes. NAFLD is considered to be an independent risk factor for cardiovascular disease and there is accumulating evidence to support a causative role in the development of chronic kidney disease (CKD). So, we aim first to assess the prevalence of chronic kidney disease in NAFLD patients, secondly to detect the association between hepatic fibrosis and CKD in NAFLD patients
Looking for future studies?
Notify Me20 year–80 year
All sexes
Observational
Sohag, Egypt
This study will be conducted on 100 patients 70 patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital, and A control group of 30 healthy volunteers who looks normal on ultrasonography from February 2021 to July 2021.
Methods:
All included patients will be subjected to:
Fasting and post-prandial blood sugar Serum lipogram. Liver function tests. Serum creatinine, Albumin -creatinine Ratio.
Ethical considerations:
The study will be approved by The Ethical committee of Sohag Faculty of Medicine, Sohag University.
The study protocol will be adherent to practice guidelines of the World Medical Association Code of Ethics (Declaration of Helsinki).
After explanation about the nature of the procedures, possible complications, benefits, and steps of the study, All patients will give a written informed consent for participating in the study, performing abdominal ultrasound, taking blood samples, performing fibroscan.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
patients diagnosed to has NAFLD by ultrasonography presented to the outpatient clinic of Sohag University Hospital
Exclusion criteria
detection of microalbuminuria in nafld patients
Other names: estimated glomerular filtration rate
Time frame: February 2021 to July 2021
Time frame: February 2021 to July 2021
Sohag University
Other
Assessment of Chronic Kidney Disease in Non Alcoholic Fatty Liver Disease(NAFLD) Patients
Acronym: NAFLD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05786482
Anxiety Disorders, Behavior
Edmonton, Alberta, Canada
View Trial DetailsNCT06161766
Chronic Disease, Chronic Kidney Diseases
Freiburg im Breisgau, Germany
View Trial DetailsNCT05056584
Chronic Disease, Chronic Kidney Diseases
Hellerup, Copenhagen, Denmark
View Trial DetailsNCT03826381
Chronic Disease, Chronic Kidney Diseases
Copenhagen, Denmark
View Trial Details